Email this article 
Post a Comment SIGNIFICANCE OF VASCULAR ENDOTHELIUM GROWTH FACTOR IN ENDOTHELIAL DYSFUNCTION AMONG PATIENTS WITH METABOLIC SYNDROME
- Authors: Shulkina SG1, Loran EA1, Smirnova EN1, Turuntseva ON1
-
Affiliations:
- Пермская государственная медицинская академия им. ак. Е. А. Вагнера, г. Пермь, Россия
- Issue: Vol 31, No 2 (2014)
- Pages: 79-85
- Section: Articles
- URL: https://journals.rcsi.science/PMJ/article/view/3248
- DOI: https://doi.org/10.17816/pmj31279-85
- ID: 3248
Cite item
Full Text
Abstract
Aim. The objective of our study was to investigate the status of endothelium in patients with metabolic syndrome. Metabolic syndrome (MS) is a block of hormonal and metabolic disorders united by a common pathophysiological mechanism - insulin resistance (IR). The connecting link between IR and cardiovascular diseases is endothelial dysfunction. Materials and methods. The problem was solved by means of assessment of vascular tonus changes using skin temperature range wavelet-analysis and VEGF determination while performing indirect cold test. Results. Serum VEGF concentration in MS patients was reliably higher than in practically healthy persons. In patients with MS, cold test response significantly differed from the control group. While carrying out cold test, the amplitude reliably decreased in endothelial and neurogenic bandwidth without its rise by the end of the study. There was revealed a reliable direct correlation between VEGF and BMI ( r =0,59; p <0,05), VEGF and WC ( r =0,58; p <0,05), VEGF and DAP ( r =0,57; p <0,05), VEGF and total cholesterol levels ( r =0,74; p <0,05). Conclusion. Thus, endothelial dysfunction in MS patients is displayed by impaired vasodilation in physiological cold test, but increase in patients’ VEGF level can be considered as an additional marker of cardiovascular risk.
About the authors
S G Shulkina
Пермская государственная медицинская академия им. ак. Е. А. Вагнера, г. Пермь, Россия
Email: shulkina-s@mail.ru
к.м.н, доцент кафедры госпитальной терапии №2
E A Loran
Пермская государственная медицинская академия им. ак. Е. А. Вагнера, г. Пермь, Россия
Email: jenushok@mail.ru
аспирант кафедры эндокринологии и клинической фармакологии
E N Smirnova
Пермская государственная медицинская академия им. ак. Е. А. Вагнера, г. Пермь, Россия
Email: elenasm2001@mail.ru
д.м.н., профессор, зав. кафедрой эндокринологии и клинической фармакологии
O N Turuntseva
Пермская государственная медицинская академия им. ак. Е. А. Вагнера, г. Пермь, Россияаспирант кафедры эндокринологии и клинической фармакологии
References
- Коваль С. Н. Снегурская И. А., Мысниченко О. В. Семейство васкулоэндотелиального фактора роста и его возможная роль в патогенезе артериальных гипертензий. Артериальная гипертензия 2012; 4 (24): 36-41.
- Рекалов Д. Г. Особенности метаболизма факторов роста у пациентов с гипертонической болезнью. Материалы науч.-практ. конф. с междунар. участием. Харков 2004; 83-84.
- Смирнова Е. Н., Подтаев С. Ю., Мизева И. А., Жукова Е. А. Нарушение механизмов вазодилатации у больных сахарным диабетом 2-го типа при проведении контралатеральной холодовой пробы. Регионарное кровообращение и микроциркуляция. Пермь 2012; 11 (1 (41)): 30-34.
- He H., Venema V. J., Gu X. [et al.] Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 1999; 274: 25130-25135.
- Smirnova E., Podtaev S., Mizeva I., Loran E. Assessment of endothelial dysfunction in patients with impaired glucose tolerance during a cold pressor test. Diabetes and Vascular Disease Research 2013; August: 1-9.
- Trape J. C., Morales R., Molina X. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand. J. Clin. Lab. Invest. 2006; 663: 261-267.
- Vyzantiadis T., Karagiannis A., Douma S., Harsoulis P., Vyzantiadis A., Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin. Exp. Hypertens 2006; 28 (7): 603-609.
- Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997; 420: 28-32.
Supplementary files
